Lannett, with a $2 billion market cap, makes thyroid, cardiovascular and pain management generic drugs.
Record Fiscal Q2 Results
On Feb 4, Lannett reported its fiscal second quarter 2015 results and blew by the Zacks Consensus Estimate by $0.15.
Earnings were $1.21 compared to the Consensus of $1.06.
Net sales jumped 71% to $114.5 million as strong sales and gross margin across several product areas boosted the quarter.
It was the 9th consecutive quarter of record net sales.
The company also has pricing power and has been able to raise prices, which has contributed to the strong growth.
Raised Full Year Guidance
For the first 6 months of fiscal 2015, net sales jumped 84% to $208.2 million.
Lannett doesn’t see performance slowing in the second half of the fiscal year. It raised net sales guidance to a range of $395 million to $405 million from $370 million to $390 million.
The analysts are equally as bullish.
3 estimates were raised since the earnings report for fiscal 2015 pushing the Zacks Consensus up sharply to $4.02 from $3.59.
That’s earnings growth of 103% as the Lannett only made $1.98 last year.
Shares Pop on Earnings News
Not surprisingly, shares rallied on the solid earnings report and are now trading near 2-year highs.
But there may be more room to run as Lannett is trading with a forward P/E of just 14. That’s under the average of the S&P 500 which is 17.4x.
For investors looking for a drug-company play with big earnings growth, Lannett is one to keep on your short list.
Want More of Our Best Recommendations?
Zacks’ Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research